Zenpep Approved for Pancreatic Disorder

powered by healthline

Average Ratings

Makes up for lack of digestive enzymes

FRIDAY, Aug. 28 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zenpep (pancrelipase) delayed-release capsules to treat a pancreatic disorder that prevents people from properly digesting food, Dutch drug maker Eurand NV said.

Exocrine pancreatic insufficiency (EPI) is caused by a lack of digestive enzymes produced by the pancreas, a possible symptom of conditions including cystic fibrosis and pancreatic cancer.

Zenpep was approved in different strengths for adults and children as young as a year old, Eurand said in a news release. It's expected to be available at U.S. pharmacies later this year.

The most common adverse reactions reported during clinical testing of Zenpep included gastrointestinal problems, abdominal pain, headache, cough and loss of weight, the company said.

More information

Learn more about this drug's approval history from the FDA.

-- Scott Roberts
Copyright © 2009 ScoutNews, LLC. All rights reserved.
Article from
Top of page
General Drug Tools
General Drug Tools view all tools
Tools for
Healthy Living
Tools for Healthy Living view all tools
Search Tools
Search Tools view all tools
Insurance Plan Tools
Insurance Plan Tools view all tools